Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 10.27%
As of Thursday, October 29, Rapport Therapeutics, Inc.’s RAPP share price has surged by 10.27%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Down 14.19%
As of Wednesday, October 28, Rapport Therapeutics, Inc.’s RAPP share price has dipped by 14.19%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 6.08%
As of Tuesday, October 27, Rapport Therapeutics, Inc.’s RAPP share price has surged by 6.08%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.71%
As of Thursday, October 22, Rapport Therapeutics, Inc.’s RAPP share price has surged by 5.71%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Down 14.99%
As of Wednesday, October 21, Rapport Therapeutics, Inc.’s RAPP share price has dipped by 14.99%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | RAPP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,534.2 | $447.1 | 51% |
|
| Shares Out (Mil) | 47.8 | 44.5 | 46% |
|
| Institutional Ownership | 95.3% | 81.1% | 67% |
|
| Float (Mil) | 46.2 | 46.4 | 45% |
|
| Beta | na | 0.76 | na |
|
| Avg Daily Volume (000s) | 1,745 | 274 | 78% |
|
| Price Change (52-week) |
(3.8%) | 55.3% | 45% |
|
| Growth | RAPP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 5.7% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 12 | |
| Current EPS | ($1.222) | ($4.039) | ($5.089) | |
| Month Ago EPS | ($1.232) | ($4.093) | ($5.229) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($1.200) | ($4.039) | ($4.830) | |
| Year/Year Chg | 45.1% | 41.1% | 93.2% | |
| Financials | RAPP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $20 | $317 | 13% |
|
| Net Income (TTM) (Mil) | ($151) | ($11) | 8% |
|
| EPS (TTM) | ($3.175) | ($0.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($121) | ($6) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($177) | $1 | 11% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $6 | 27% |
|
| Enterprise Value (Q1) (Mil) | $1,120 | $458 | 42% |
|
| Valuation | RAPP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.19 | 2.16 | 69% |
|
| P/E | na | 18.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.3 | na |
|
| Ratios | RAPP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 69.4% | 96% |
|
| Net Margin | (752.4%) | 3.3% | 1% |
|
| ROA | (31.5%) | (22.2%) | 16% |
|
| ROE | (33.3%) | (21.8%) | 19% |
|
| Liabilities to Assets | 6.5% | 31.8% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
Rapport Therapeutics, Inc. did not pass any screens on 11/4/2026.
